Comparison of the long-term outcomes of uncinate process cancer and non-uncinate process pancreas head cancer: poor prognosis accompanied by early locoregional recurrence
- 325 Downloads
The embryologic and anatomic peculiarity of the uncinate process may result in distinct clinical features, but few studies have addressed the uncinate process cancer. The purpose of this study was to compare the clinicopathologic characteristics and identify the prognostic factors that affect the survival and recurrence of pancreatic head cancer by tumor location.
Between January 2002 and December 2008, 453 patients (161 with uncinate and 292 with non-uncinate process cancer) were treated for pancreatic head cancer. Clinicopathologic variables were analyzed by tumor location.
Invasion into the superior mesenteric artery (SMA) occurred more frequently (p < 0.001), and overall resectability (p = 0.003), curative resection (p < 0.001), and R0 resection rates (22.3% vs 35.6%; p = 0.003) were lower for uncinate process cancer. Furthermore, overall survival after R0 resection was lower for uncinate process cancer (median 21 vs 26 months; p = 0.018), and this was accompanied by more frequent (p = 0.038) and earlier (median 13 vs 52 months; p < 0.001) locoregional recurrence. Concurrent chemoradiation increased overall (median, 26 vs 13 months; p < 0.001) and disease-free survival (median, 15 vs 6 months; p < 0.001) of uncinate and non-uncinate process cancer, respectively, after curative-intended resection.
In uncinate process cancer, frequent invasion into the SMA led to lower resectability. Furthermore, lower survival after R0 resection was accompanied with frequent and early locoregional recurrence. Strategies to improve surgical and perioperative locoregional control are required for uncinate process cancer.
KeywordsPancreatic cancer Recurrence Survival analysis
This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (no. 0820030).
- 12.Han SS, Kim SW, Choi JI, Choi MG, Park YC, Jang JY, Park YH (2005) Determination of resectability for pancreatic cancer: based on the suspected vascular invasion in abdominal computed tomography. Korean J HBP Surg 9:55–61Google Scholar
- 15.Barugola G, Falconi M, Bettini R, Boninsegna L, Casarotto A (2007) The determinant factors of recurrence following resection for ductal pancreatic cancer. JOP 9:132–140Google Scholar
- 19.American Joint Committee on Cancer (2002) Exocrine pancreas. In: AJCC cancer staging manual. Springer, New York, 157–164Google Scholar
- 22.Moertel CG, Childs DS Jr, Reitemeir RJ, Colby MY Jr, Holbrook MA (1967) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865–867Google Scholar
- 23.Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The Gastrointestinal Study Group. Cancer 48:1705–1710CrossRefPubMedGoogle Scholar
- 25.Klinkenbijil JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230:776–784CrossRefGoogle Scholar
- 29.National Comprehensive Cancer Network. Practice guidelines in oncology. http://www.nccn.org
- 32.Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966CrossRefPubMedGoogle Scholar